Trial Profile
A Phase III (Phase V Program), Open-Label, Randomized, Referred-Care-Controlled, Clinical Trial to Study the Efficacy and Safety of MK0217A/Alendronate Sodium-70 mg/Vitamin D3 5600 I.U. Combination Tablet on Vitamin D Inadequacy in the Treatment of Osteoporosis in Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Alendronic acid/colecalciferol (Primary) ; Calcium; Osteoporosis therapies
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Organon
- 19 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 28 Apr 2012 Planned number of patients changed from 800 to 840 as reported by European Clinical Trials Database record.
- 17 Dec 2009 Planned end date changed from 1 Jan 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.